Postmenopausal women account for about 66 percent of people with Alzheimer’s disease, or AD, and related dementias. A rapid drop in estrogen and earlier menopause are linked to neurodegenerative risk, suggesting hormones may influence disease susceptibility.

A new study from the Karolinska Institutet in Sweden builds on this link, connecting estrogen levels to cholesterol metabolites that may serve as early indicators of brain health. The findings were published in the Journal of Lipid Research.

“AD pathology develops decades before clinical symptoms emerge,” said Sylvia Maioli, an associate professor and senior author on the study.

The researchers focused on oxysterols, oxidized cholesterol metabolites that can cross the blood–brain barrier and influence gene regulation. These molecules can reflect both brain cholesterol turnover and systemic lipid metabolism, making them promising candidates for blood-based biomarkers.

Previous work from Maioli’s lab showed that one oxysterol, 24(S)-hydroxycholesterol, or 24HC, can protect against memory loss in female mice during aging and menopause-like conditions.

“These findings prompted us to further explore the relationship between oxysterols and sex hormones like estrogen,” Maioli said.

To test this relationship in humans, the team analyzed data from the Women’s Health Initiative, a large, well-characterized cohort of postmenopausal women. The Women’s Health Initiative includes decades of longitudinal data on postmenopausal women, allowing researchers to examine links between hormones, metabolism and disease risk at scale.

They measured levels of 24HC, 27-hydroxycholesterol, or 27HC, and 24,25-epoxycholesterol, or 24,25-EPOXY. These molecules are oxidized cholesterol derivatives that act as signaling molecules in lipid homeostasis and reflect both brain cholesterol turnover and systemic cholesterol metabolism.

Bioavailable estradiol was positively associated with both 24HC and 27HC. In individuals carrying apolipoprotein E variant 4, or APOE4, a known genetic risk factor for Alzheimer’s disease, 24HC was also associated with estradiol and estrone, the dominant estrogen after menopause.

Because both oxysterols have been linked to Alzheimer’s pathology, these associations suggest a potential biochemical link between hormone levels and disease risk.

Oxysterol levels were not associated with reproductive history, regardless of APOE4 status. The only exception was a marginal association in participants taking cholesterol-lowering medications.

Some findings were less straightforward. The positive association between 27HC and estradiol was unexpected. The researchers speculated that elevated 27HC may reduce estrogen’s protective effects, prompting the body to maintain or increase estradiol levels. However, previous studies have not consistently supported this explanation.

“Given that 24HC and 27HC have both been tied to AD risk, our findings suggest that female-specific factors like estrogen and age at menopause could play a role in the lipid-related mechanisms underlying AD development,” said Maioli.

Despite these uncertainties, the researchers say the work could help identify biomarkers for early disease detection and deepen understanding of how cholesterol metabolism contributes to AD. Such biomarkers could help identify at-risk individuals before symptoms appear.

“We hope our study will encourage future large-scale investigations to further clarify the role of oxysterols and reproductive factors in AD risk,” Maioli said.

Together, the findings suggest that hormone-driven lipid metabolism may be an underexplored factor in Alzheimer’s risk in women.